Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
esophageal cancer
Biotech
ESMO: Jazz HER2 bispecific posts 59% survival at 30 months
The 30-month data unveiled at ESMO gave other insights into zanidatamab’s efficacy, including a confirmed objective response rate of 84%.
James Waldron
Sep 16, 2024 3:00am
Number of esophageal cancer trials rise with incidence rate
Jul 31, 2024 3:20pm
Exact shows off its pill-on-a-string test for esophageal cancer
Mar 28, 2024 11:00am
Roche racks up phase 3 TIGIT win, but trial design leaves doubts
Jan 17, 2024 5:34am
Zymeworks links HER2 bispecific to 84% survival at 18 months
Jan 19, 2023 9:55am
PAVmed and its Lucid, Veris subsidiaries lay off 20% of staff
Jan 18, 2023 11:11am
